A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.

Hu, Han; Zhang, Siqi; Cai, Linkang; Duan, Haixiao; Li, Yuying; Yang, Junhan; Wang, Yang; Liu, Biao; Dong, Shuang; Fang, Zhizheng; Liu, Binlei

Hu, Han; Zhang, Siqi; Cai, Linkang; Duan, Haixiao; Li, Yuying; Yang, Junhan; Wang, Yang; Liu, Biao; Dong, Shuang; Fang, Zhizheng; Liu, Binlei.

Afiliação

Hu H; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China.
Zhang S; Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
Cai L; Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
Duan H; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China.
Li Y; Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
Yang J; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China.
Wang Y; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China.
Liu B; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China.
Dong S; Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Fang Z; Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, China.
Liu B; National ''111'' Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China. liubl@h

Virol J ; 19(1): 74, 2022 04 22.

Article em En | MEDLINE | ID: mdl-35459242

Assuntos

Neoplasias; Terapia Viral Oncolítica; Vírus Oncolíticos; Animais; Vetores Genéticos/genética; Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética; Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico; Herpesvirus Humano 2/genética; Interleucina-12/genética; Interleucina-15/genética; Interleucina-7/genética; Camundongos; Neoplasias/tratamento farmacológico; Terapia Viral Oncolítica/métodos; Vírus Oncolíticos/genética

Palavras-chave

4T1; CT26; Combined therapy; Oncolytic herpes simplex virus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Vírus Oncolíticos / Terapia Viral Oncolítica / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Virol J Assunto da revista: VIROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google